Evaluating STC-1 and STC-2 mRNA expressions in Schizophrenia patients with increased oxidative stress; [Évaluation des expressions d'ARNm de STC-1 et STC-2 chez des patients schizophrènes présentant un stress oxydatif accru]

MakaleAçık ErişimScopus SJRQ2
  • SDG 3 · Sağlık ve Kaliteli Yaşam

Özet

Introduction: Schizophrenia is a chronic psychiatric disorder characterized by cognitive impairment. Oxidative stress is associated with disease progression in patients with schizophrenia. Stanniocalcin (STC)-1 and STC-2 are two proteins commonly expressed in mammals belonging to the stanniocalcin family and they are involved in oxidative stress. The aim of this study is to investigate STC-1 and STC-2 mRNA expressions in schizophrenia patients with altered oxidative stress parameters. Methods: For this purpose, 70 patients with schizophrenia and 40 healthy individuals were recruited for the study. Peripheral blood samples were obtained from all participants. Glutathione (GSH) activities, superoxide dismutase (SOD) activities, and malondialdehyde (MDA) levels were measured. STC-1 and STC-2 expressions were assessed by real-time polymerase chain reactions. Results: SOD activity levels were lower in patients than in healthy individuals (p = 0.0309), while the patients’ MDA levels were higher (p = 0.039). STC-1 and STC-2 expressions were lower in patients than in healthy individuals (p = 0.1049 and p < 0.0001, respectively). Furthermore, these two genes had a positive correlation among the patients (r = 0.435, p = 0.0025). According to area under the curve (AUC) values, STC-2 (AUC = 0.8332, p < 0.0001) had better diagnostic power than STC-1 (AUC = 0.6167, p = 0.1037). Conclusions: The expression of stanniocalcins in schizophrenia was investigated here for the first time. Decreased STC-2 expression in patients with schizophrenia with increased oxidative stress parameters may guide the understanding of the pathophysiological mechanisms caused by oxidative stress, which may be increased in cognitive diseases such as schizophrenia, and it also has the potential to be a prognostic factor that can be used in the diagnosis of schizophrenia.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/bayburt/10904Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1016/j.amp.2023.02.005Yayıncı resmi DOI adresi
İndeks kayıtları
Kaydın indeks veri tabanlarındaki sayfası (aktarımda alınan kayıt numarasıyla). Erişim, indeksin kendi koşullarına bağlıdır.
Atıflar
Scopus
0
WoS
0
OpenAlex
0
Her kaynağın kendi saydığı toplam atıf; aktarım ve zenginleştirme sırasında alındı.
Tam Kayıt
AlanDeğerDil
dc.contributor.authorKarabulut Uzunçakmak, Sevgi
dc.contributor.authorÖzcan, Halil
dc.contributor.authorDirican, Ebubekir
dc.contributor.authorTavacı Özçelik, Ayşegül
dc.date.accessioned2026-10-29T19:07:51.420429788Z
dc.date.available2026-10-29T19:07:51.420429788Z
dc.date.issued2024
dc.description.abstractIntroduction: Schizophrenia is a chronic psychiatric disorder characterized by cognitive impairment. Oxidative stress is associated with disease progression in patients with schizophrenia. Stanniocalcin (STC)-1 and STC-2 are two proteins commonly expressed in mammals belonging to the stanniocalcin family and they are involved in oxidative stress. The aim of this study is to investigate STC-1 and STC-2 mRNA expressions in schizophrenia patients with altered oxidative stress parameters. Methods: For this purpose, 70 patients with schizophrenia and 40 healthy individuals were recruited for the study. Peripheral blood samples were obtained from all participants. Glutathione (GSH) activities, superoxide dismutase (SOD) activities, and malondialdehyde (MDA) levels were measured. STC-1 and STC-2 expressions were assessed by real-time polymerase chain reactions. Results: SOD activity levels were lower in patients than in healthy individuals (p = 0.0309), while the patients’ MDA levels were higher (p = 0.039). STC-1 and STC-2 expressions were lower in patients than in healthy individuals (p = 0.1049 and p < 0.0001, respectively). Furthermore, these two genes had a positive correlation among the patients (r = 0.435, p = 0.0025). According to area under the curve (AUC) values, STC-2 (AUC = 0.8332, p < 0.0001) had better diagnostic power than STC-1 (AUC = 0.6167, p = 0.1037). Conclusions: The expression of stanniocalcins in schizophrenia was investigated here for the first time. Decreased STC-2 expression in patients with schizophrenia with increased oxidative stress parameters may guide the understanding of the pathophysiological mechanisms caused by oxidative stress, which may be increased in cognitive diseases such as schizophrenia, and it also has the potential to be a prognostic factor that can be used in the diagnosis of schizophrenia.
dc.identifier.doi10.1016/j.amp.2023.02.005
dc.identifier.eissn1769-6631
dc.identifier.endpage790
dc.identifier.issn0003-4487
dc.identifier.issue9
dc.identifier.scopus2-s2.0-85150428201
dc.identifier.startpage785
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/bayburt/10904
dc.identifier.volume182
dc.identifier.wosWOS:001361396000001
dc.language.isoen
dc.publisherElsevier Masson s.r.l.
dc.relation.ispartofAnnales Medico-Psychologiques
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectOxidative stress
dc.subjectSchizophrenia
dc.subjectStanniocalcin
dc.subjectSTC-1
dc.subjectSTC-2
dc.subject.classificationPharmacology & Pharmacy
dc.subject.classificationPsychiatry
dc.subject.classificationPsychology
dc.subject.classificationPsychology, Multidisciplinary
dc.subject.otheraripiprazole
dc.subject.otherclozapine
dc.subject.otherglutathione
dc.subject.otherhypocalcin
dc.subject.otherhypocalcin 1
dc.subject.otherhypocalcin 2
dc.subject.othermalonaldehyde
dc.subject.othermessenger RNA
dc.subject.otherolanzapine
dc.subject.otherpaliperidone
dc.subject.otherrisperidone
dc.subject.othersuperoxide dismutase
dc.subject.otherunclassified drug
dc.subject.otheradult
dc.subject.otheraged
dc.subject.otherArticle
dc.subject.othercontrolled study
dc.subject.othercorrelation analysis
dc.subject.otherfemale
dc.subject.othergene expression
dc.subject.otherhuman
dc.subject.othermajor clinical study
dc.subject.othermale
dc.subject.otheroxidative stress
dc.subject.otherprotein expression
dc.subject.otherreceiver operating characteristic
dc.subject.otherschizophrenia
dc.titleEvaluating STC-1 and STC-2 mRNA expressions in Schizophrenia patients with increased oxidative stress; [Évaluation des expressions d'ARNm de STC-1 et STC-2 chez des patients schizophrènes présentant un stress oxydatif accru]
dc.typeArticle
rdl.citation.openalex0
rdl.citation.scopus0
rdl.citation.wos0
rdl.oa.statusgreen
rdl.oa.statusclosed
rdl.oa.urlhttp://hdl.handle.net/20.500.12403/3958
rdl.scopus.quartileQ2
rdl.sdgSDG03
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)